首页> 美国卫生研究院文献>NPJ Primary Care Respiratory Medicine >Validation of the breathlessness cough and sputum scale to predict COPD exacerbation
【2h】

Validation of the breathlessness cough and sputum scale to predict COPD exacerbation

机译:验证呼吸困难咳嗽和痰液量表以预测COPD恶化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The breathlessness, cough and sputum scale (BCSS) is a three-item questionnaire rating breathlessness, cough and sputum on a 5-point Likert scale from 0 (no symptoms) to 4 (severe symptoms). Researchers have explored the utility of this tool to quantify efficacy of treatment following a chronic obstructive pulmonary disease (COPD) exacerbation; however, little work has been done to investigate the ability of the BCSS to predict COPD exacerbation. As part of a prospective case-crossover study among a cohort of 168 COPD patients residing in central Massachusetts, patients were asked standard BCSS questions during exacerbation and randomly identified non-exacerbation (or healthy) weeks. We found that the BCSS was strongly associated with COPD exacerbation (OR=2.80, 95% CI=2.27–3.45) and that a BCSS sum score of 5.0 identified COPD exacerbation with 83% sensitivity and 68% specificity. These results may be useful in the clinical setting to expedite interventions of exacerbation.
机译:呼吸困难,咳嗽和痰量表(BCSS)是一项三项问卷,以5分李克特量表从0(无症状)到4(严重症状)对呼吸困难,咳嗽和痰进行评分。研究人员已经探索了该工具的实用性,以量化慢性阻塞性肺疾病(COPD)恶化后的治疗效果。然而,很少有工作来研究BCSS预测COPD恶化的能力。作为一项前瞻性病例交叉研究的一部分,该研究纳入了马萨诸塞州中部的168名COPD患者,在加重期间向患者询问标准BCSS问题,并随机确定未加重(或健康)的几周。我们发现,BCSS与COPD恶化密切相关(OR = 2.80,95%CI = 2.27–3.45),BCSS总分5.0表示COPD恶化,敏感性为83%,特异性为68%。这些结果在临床环境中可能有助于加速病情加重。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号